Retiza, Reymar L.

HRN: 22-23-14  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/18/2022
CEFTRIAXONE 1G (VIAL)
11/18/2022
11/24/2022
IV
2g
OD
UTI
Waiting Final Action 
11/21/2022
RIFAXIMIN 200MG (TAB)
11/21/2022
11/28/2022
PO
200 Mg
BID
Hepatic Encephalopathy
Waiting Final Action 
11/23/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/23/2022
12/06/2022
IV
500mg
Q8
Intraabdominal Infection
Waiting Final Action 
11/30/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/30/2022
12/07/2022
IV
500mg
Q6
Sepsis
Waiting Final Action 
11/30/2022
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
11/30/2022
12/07/2022
IV
2.25gms
Q12
Sepsis
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: